Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.

Hologic (HOLX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Hologic’s latest update keeps its fair value estimate steady at about US$76.60 per share, signaling no change to the headline price target in current analyst models. That stability comes as research ...

While the broader market has struggled with the S&P 500 down 1% since September 2025, Hologic has surged ahead as its stock ...

Hologic, a Marlborough-based medical device manufacturer, is expanding its product catalog through the planned $310-million acquisition of Endomagnetics, a breast cancer surgery technology developer.

--Powerful artificial intelligence combined with digital imaging designed to transform the screening process-- Genius™ Digital Diagnostics System for Cervical Cancer Screening With the Genius Digital ...

FDA places stereotactic breast biopsy needles on shortage list, with supply issues expected to continue into early 2027 ...

In its fifth year, the annual Hologic Global Women’s Health Index found only minimal improvements in preventive screening rates from the first report, and no change at all in an overall analysis of ...

Hologic’s HOLX Molecular Diagnostics business posted a 7.8% (excluding COVID-19-related sales) growth in the second quarter of fiscal 2025, although results did not reflect its full potential.The ...

Women’s health tech company Hologic is launching "Better is Possible," a new health education and awareness campaign aimed at getting women to talk to their doctors about their disruptive period ...

Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography. The study, conducted at Massachusetts General Hospital and ...

Hologic stock (NASDAQ NDAQ: HOLX), a medical devices company focused on women’s health, has seen a 19% fall this year, faring slightly better than the broader S&P500 index, down 24%. Even if we look ...